Integrated BioPharma, Inc. (INBP)
OTCMKTS
· Delayed Price · Currency is USD
0.290
-0.030 (-9.38%)
Nov 7, 2024, 3:00 PM EST
Integrated BioPharma Income Statement
Financials in millions USD. Fiscal year is July - June.
Millions USD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 | Jun '20 Jun 30, 2020 | 2019 - 2015 |
| Revenue | 50.32 | 50.32 | 50.67 | 56.25 | 63.56 | 52.77 | Upgrade
|
| Revenue Growth (YoY) | -0.70% | -0.70% | -9.91% | -11.51% | 20.45% | 5.59% | Upgrade
|
| Cost of Revenue | 46.43 | 46.43 | 46.61 | 49.69 | 54.08 | 46.04 | Upgrade
|
| Gross Profit | 3.88 | 3.88 | 4.06 | 6.55 | 9.48 | 6.73 | Upgrade
|
| Selling, General & Admin | 3.63 | 3.63 | 3.94 | 3.81 | 3.7 | 3.47 | Upgrade
|
| Operating Expenses | 3.63 | 3.63 | 3.94 | 3.81 | 3.7 | 3.47 | Upgrade
|
| Operating Income | 0.25 | 0.25 | 0.12 | 2.75 | 5.78 | 3.26 | Upgrade
|
| Interest Expense | - | - | -0.01 | -0.13 | -0.26 | -0.4 | Upgrade
|
| Interest & Investment Income | 0.02 | 0.02 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -0 | -0 | -0.01 | 0.01 | 0.06 | 0.05 | Upgrade
|
| EBT Excluding Unusual Items | 0.27 | 0.27 | 0.1 | 2.63 | 5.59 | 2.91 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -0.06 | 0 | 0.18 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | 0.02 | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | 1.66 | - | Upgrade
|
| Pretax Income | 0.27 | 0.27 | 0.1 | 2.6 | 7.25 | 3.09 | Upgrade
|
| Income Tax Expense | 0.16 | 0.16 | 0.13 | -1.24 | -0.77 | -1.02 | Upgrade
|
| Net Income | 0.11 | 0.11 | -0.03 | 3.84 | 8.01 | 4.11 | Upgrade
|
| Net Income to Common | 0.11 | 0.11 | -0.03 | 3.84 | 8.01 | 4.11 | Upgrade
|
| Net Income Growth | - | - | - | -52.10% | 95.06% | 143.36% | Upgrade
|
| Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 30 | Upgrade
|
| Shares Outstanding (Diluted) | 31 | 31 | 30 | 32 | 32 | 31 | Upgrade
|
| Shares Change (YoY) | 3.09% | 3.09% | -7.34% | 0.65% | 3.07% | 5.31% | Upgrade
|
| EPS (Basic) | 0.00 | 0.00 | -0.00 | 0.13 | 0.27 | 0.14 | Upgrade
|
| EPS (Diluted) | 0.00 | 0.00 | -0.00 | 0.12 | 0.25 | 0.13 | Upgrade
|
| EPS Growth | - | - | - | -52.00% | 92.31% | 122.81% | Upgrade
|
| Free Cash Flow | 0.39 | 0.39 | 1.12 | 3.61 | 2.76 | 1.13 | Upgrade
|
| Free Cash Flow Per Share | 0.01 | 0.01 | 0.04 | 0.11 | 0.09 | 0.04 | Upgrade
|
| Gross Margin | 7.72% | 7.72% | 8.01% | 11.65% | 14.92% | 12.75% | Upgrade
|
| Operating Margin | 0.50% | 0.50% | 0.24% | 4.88% | 9.10% | 6.18% | Upgrade
|
| Profit Margin | 0.22% | 0.22% | -0.07% | 6.82% | 12.61% | 7.78% | Upgrade
|
| Free Cash Flow Margin | 0.78% | 0.78% | 2.20% | 6.41% | 4.33% | 2.13% | Upgrade
|
| EBITDA | 0.57 | 0.57 | 0.47 | 3.08 | 6.12 | 3.57 | Upgrade
|
| EBITDA Margin | 1.13% | 1.13% | 0.93% | 5.48% | 9.63% | 6.77% | Upgrade
|
| D&A For EBITDA | 0.32 | 0.32 | 0.35 | 0.34 | 0.34 | 0.31 | Upgrade
|
| EBIT | 0.25 | 0.25 | 0.12 | 2.75 | 5.78 | 3.26 | Upgrade
|
| EBIT Margin | 0.50% | 0.50% | 0.24% | 4.88% | 9.10% | 6.18% | Upgrade
|
| Effective Tax Rate | 58.21% | 58.21% | 134.00% | - | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.